In a murine model of non-alcoholic fatty liver disease, downregulation of miR-130b-5p, which targets IGFBP-2, prevented lipid accumulation and insulin resistance by increasing IGFBP-2 and AKT activation [80]. This evidence concerns the gene IGFBP2 and metabolic dysfunction-associated steatotic liver disease.